Victory Capital Management Inc. Has $1.27 Million Position in Alnylam Pharmaceuticals, Inc. (ALNY)

Victory Capital Management Inc. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,815 shares of the biopharmaceutical company’s stock after buying an additional 4,725 shares during the period. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,272,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. A.R.T. Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $1,598,000. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $24,885,000. AQR Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $1,036,000. UBS Asset Management Americas Inc. increased its stake in shares of Alnylam Pharmaceuticals by 9.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,667,426 shares of the biopharmaceutical company’s stock worth $62,429,000 after buying an additional 148,664 shares during the period. Finally, Opus Point Partners Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 97.0% in the fourth quarter. Opus Point Partners Management LLC now owns 88,784 shares of the biopharmaceutical company’s stock worth $3,324,000 after buying an additional 43,720 shares during the period. Institutional investors own 90.04% of the company’s stock.

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 81.38 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $84.18. The stock’s market cap is $7.01 billion. The stock has a 50 day moving average price of $67.47 and a 200 day moving average price of $51.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The firm’s quarterly revenue was up 160.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.21) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.30) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Victory Capital Management Inc. Has $1.27 Million Position in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally reported by sleekmoney and is the property of of sleekmoney. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://sleekmoney.com/victory-capital-management-inc-has-1-27-million-position-in-alnylam-pharmaceuticals-inc-alny/1927381.html.

ALNY has been the topic of a number of recent analyst reports. Credit Suisse Group downgraded Alnylam Pharmaceuticals to a “hold” rating and set a $50.00 price objective on the stock. in a research report on Monday, March 20th. Vetr upgraded Alnylam Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $52.94 price objective on the stock in a research report on Wednesday, February 22nd. ValuEngine upgraded Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies set a $118.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 15th. Finally, FBR & Co reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, March 20th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average target price of $71.29.

In other news, EVP Akshay Vaishnaw sold 11,000 shares of the company’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the sale, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the sale, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock worth $4,325,000 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/victory-capital-management-inc-has-1-27-million-position-in-alnylam-pharmaceuticals-inc-alny/1927381.html

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *